

Erratum

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries**Ernest Choy¹, Roberto Caporali², Ricardo Xavier³, Bruno Fautrel⁴, Raimón Sanmarti⁵, Min Bao⁶, Corrado Bernasconi⁷ and Attila Pethö-Schramm⁷**

Rheumatology 2018;57:499–507.
doi:10.1093/rheumatology/kex443

The above paper was printed with an error in the copyright line. This copyright line has now been corrected online, and should be:

© The Author(s) 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology.

The Publishers would like to apologise for this error.

¹CREATE Centre, Division of Infection and Immunity, Cardiff University, Cardiff, UK, ²Division of Rheumatology, University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ³Department of Medicine, Universidade Federal do Rio Grande do Sul Porto Alegre, Rio Grande do Sul, Brazil, ⁴Department of Rheumatology, APHP, Pitié Salpêtrière Hospital, Pierre and Marie Curie University, Paris, France, ⁵Department of Rheumatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain, ⁶Genentech, South San Francisco, CA, USA and ⁷F. Hoffmann-La Roche, Basel, Switzerland

Correspondence to: Ernest Choy, UK CREATE Centre and Welsh Arthritis Research Network, Cardiff University School of Medicine, Tenovus Building, Health Park Campus, Cardiff CF14 4XN, UK.
E-mail: choyeh@cardiff.ac.uk